Symbols / MCRB $8.89 +0.68% Seres Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
MCRB Chart
About

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 85.22M
Enterprise Value 122.42M Income 5.70M Sales 789.00K
Book/sh 4.63 Cash/sh 4.77 Dividend Yield —
Payout 0.00% Employees 66 IPO —
P/E 13.89 Forward P/E -0.97 PEG —
P/S 108.01 P/B 1.92 P/C —
EV/EBITDA -1.36 EV/Sales 155.16 Quick Ratio 2.40
Current Ratio 2.56 Debt/Eq 187.63 LT Debt/Eq —
EPS (ttm) 0.64 EPS next Y -9.17 EPS Growth —
Revenue Growth — Earnings 2026-05-06 ROA -42.25%
ROE 19.64% ROIC — Gross Margin 0.00%
Oper. Margin -44.24% Profit Margin 7.22% Shs Outstand 9.59M
Shs Float 7.28M Short Float 9.61% Short Ratio 12.51
Short Interest — 52W High 29.98 52W Low 6.53
Beta 0.26 Avg Volume 66.46K Volume 105.12K
Target Price $22.00 Recom None Prev Close $8.83
Price $8.89 Change 0.68%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.00
Mean price target
2. Current target
$8.89
Latest analyst target
3. DCF / Fair value
$-103.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.89
Low
$22.00
High
$22.00
Mean
$22.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 main Canaccord Genuity Buy → Buy $22
2025-09-24 main Canaccord Genuity Buy → Buy $22
2025-05-08 down Chardan Capital Buy → Neutral $6
2025-03-20 main Chardan Capital Buy → Buy $1
2025-03-14 main Goldman Sachs Sell → Sell $1
2024-11-14 main Canaccord Genuity Buy → Buy $10
2024-11-13 main Chardan Capital Buy → Buy $1
2024-10-24 down JP Morgan Neutral → Underweight —
2024-09-13 main Canaccord Genuity Buy → Buy $10
2024-08-14 main Canaccord Genuity Buy → Buy $10
2024-08-14 main Chardan Capital Buy → Buy $1
2024-06-07 down Oppenheimer Outperform → Perform —
2024-06-07 main Canaccord Genuity Buy → Buy $10
2024-05-09 main Oppenheimer Outperform → Outperform $4
2024-05-08 main Chardan Capital Buy → Buy $6
2024-03-06 main Oppenheimer Outperform → Outperform $5
2024-03-06 main Chardan Capital Buy → Buy $8
2024-01-16 main Oppenheimer Outperform → Outperform $9
2023-11-03 main Goldman Sachs Sell → Sell $1
2023-04-28 main Chardan Capital — → Buy $10
News
RSS: Latest MCRB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-13 DESROSIER THOMAS J Chief Executive Officer — 78 $8.47 $661
2026-02-13 DESROSIER THOMAS J Chief Executive Officer — 244 — —
2026-02-13 SHAFF ERIC D Director — 259 $8.47 $2,194
2026-02-13 SHAFF ERIC D Director — 723 — —
2026-02-13 HENN MATTHEW R Officer — 89 $8.47 $754
2026-02-13 HENN MATTHEW R Officer — 239 — —
2026-02-13 YOUNG TERESA L. Officer — 75 $8.47 $635
2026-02-13 YOUNG TERESA L. Officer — 231 — —
2025-11-14 DESROSIER THOMAS J Chief Executive Officer — 76 $17.30 $1,315
2025-11-14 DESROSIER THOMAS J Chief Executive Officer — 244 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.79
0.00
0.00
0.00
Operating Revenue
0.79
0.00
0.00
0.00
Cost Of Revenue
6.54
+85.28%
3.53
0.00
0.00
Reconciled Cost Of Revenue
6.54
+85.28%
3.53
0.00
0.00
Gross Profit
-5.75
-62.94%
-3.53
0.00
0.00
Operating Expense
88.22
-25.10%
117.78
-39.63%
195.10
+8.44%
179.91
Research And Development
49.06
-24.06%
64.60
-45.07%
117.60
+7.25%
109.65
Selling General And Administration
39.16
-26.37%
53.18
-31.38%
77.50
+10.30%
70.26
General And Administrative Expense
39.16
-26.37%
53.18
-31.38%
77.50
+10.30%
70.26
Salaries And Wages
14.41
-36.45%
22.68
-38.08%
36.63
+17.11%
31.28
Other Gand A
24.74
-18.89%
30.50
-60.64%
77.50
+10.30%
70.26
Other Operating Expenses
—
—
0.70
-29.88%
1.00
Total Expenses
94.76
-21.89%
121.31
-37.82%
195.10
+8.44%
179.91
Operating Income
-93.97
+22.54%
-121.31
+37.82%
-195.10
-8.44%
-179.91
Total Operating Income As Reported
-93.97
+22.54%
-121.31
+37.82%
-195.10
-8.44%
-179.91
EBITDA
9.83
+108.17%
-120.30
+33.69%
-181.42
-6.14%
-170.93
Normalized EBITDA
-70.86
+43.76%
-125.99
+30.55%
-181.42
-6.14%
-170.93
Reconciled Depreciation
4.13
-24.41%
5.47
-12.41%
6.24
-5.82%
6.63
EBIT
5.70
+104.53%
-125.77
+32.98%
-187.66
-5.69%
-177.56
Total Unusual Items
80.69
+1319.51%
5.68
0.00
0.00
Total Unusual Items Excluding Goodwill
80.69
+1319.51%
5.68
0.00
0.00
Special Income Charges
80.69
+1319.51%
5.68
0.00
0.00
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Pretax Income
5.70
+104.53%
-125.77
+33.85%
-190.13
-3.57%
-183.58
Net Non Operating Interest Income Expense
2.23
-43.86%
3.97
-17.92%
4.83
+263.17%
-2.96
Interest Expense Non Operating
0.00
0.00
-100.00%
2.47
-59.00%
6.02
Net Interest Income
2.23
-43.86%
3.97
-17.92%
4.83
+263.17%
-2.96
Interest Expense
0.00
0.00
-100.00%
2.47
-59.00%
6.02
Interest Income Non Operating
2.23
-43.86%
3.97
-45.66%
7.30
+138.75%
3.06
Interest Income
2.23
-43.86%
3.97
-45.66%
7.30
+138.75%
3.06
Other Income Expense
97.44
+1256.83%
-8.42
-6385.82%
0.13
+119.01%
-0.70
Other Non Operating Income Expenses
16.75
+218.77%
-14.11
-10627.61%
0.13
+119.01%
-0.70
Gain On Sale Of Business
80.69
+1319.51%
5.68
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Net Income From Continuing Operation Net Minority Interest
5.70
+104.53%
-125.77
+33.85%
-190.13
-3.57%
-183.58
Net Income From Continuing And Discontinued Operation
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Net Income Continuous Operations
5.70
+104.53%
-125.77
+33.85%
-190.13
-3.57%
-183.58
Net Income Discontinuous Operations
0.00
-100.00%
125.91
+64.79%
76.41
+214.77%
-66.58
Normalized Income
-74.99
+42.95%
-131.46
+30.86%
-190.13
-3.57%
-183.58
Net Income Common Stockholders
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Diluted EPS
0.64
0.00
+100.00%
-17.77
+61.54%
-46.20
Basic EPS
0.64
0.00
+100.00%
-17.77
+61.54%
-46.20
Basic Average Shares
8.86
+14.02%
7.77
+21.40%
6.40
+18.44%
5.40
Diluted Average Shares
8.87
+14.16%
7.77
+21.40%
6.40
+18.44%
5.40
Diluted NI Availto Com Stockholders
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
138.19
-1.16%
139.81
-61.01%
358.60
+2.81%
348.78
Current Assets
49.38
+27.67%
38.67
-77.95%
175.41
-9.94%
194.76
Cash Cash Equivalents And Short Term Investments
45.77
+48.62%
30.79
-75.94%
127.97
-29.43%
181.34
Cash And Cash Equivalents
45.77
+48.62%
30.79
-75.94%
127.97
-21.51%
163.03
Other Short Term Investments
—
—
0.00
-100.00%
18.31
Receivables
0.52
-89.12%
4.75
0.00
0.00
Accounts Receivable
0.52
-75.00%
2.07
0.00
—
Other Receivables
—
2.68
—
—
Inventory
—
—
29.65
0.00
Raw Materials
—
—
4.43
0.00
Work In Process
—
—
25.22
0.00
Finished Goods
—
—
0.00
0.00
Prepaid Assets
—
—
—
—
Assets Held For Sale Current
—
0.00
-100.00%
39.40
—
Other Current Assets
3.09
-1.18%
3.13
-61.11%
8.05
-40.04%
13.42
Total Non Current Assets
88.82
-12.18%
101.14
-44.79%
183.19
+18.94%
154.02
Net PPE
80.12
-13.33%
92.44
-14.43%
108.03
-19.36%
133.97
Gross PPE
136.73
-6.11%
145.63
-7.30%
157.11
-12.23%
179.01
Accumulated Depreciation
-56.61
-6.42%
-53.20
-8.39%
-49.08
-8.97%
-45.04
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
8.58
+1.59%
8.45
+0.27%
8.42
+19.52%
7.05
Construction In Progress
0.86
+0.00%
0.86
-22.71%
1.11
-71.94%
3.97
Other Properties
96.33
-8.58%
105.37
-8.44%
115.08
-15.08%
135.52
Leases
30.95
+0.00%
30.95
-4.72%
32.49
+0.05%
32.47
Investments And Advances
—
—
—
0.00
Other Non Current Assets
8.70
+0.00%
8.70
-88.43%
75.16
+274.84%
20.05
Total Liabilities Net Minority Interest
93.97
-25.43%
126.03
-68.76%
403.46
+19.37%
338.00
Current Liabilities
19.32
-53.13%
41.22
-58.22%
98.66
+15.26%
85.60
Payables And Accrued Expenses
8.93
-72.56%
32.55
+24.47%
26.15
-66.16%
77.28
Payables
1.68
-58.76%
4.08
+12.03%
3.64
-93.03%
52.21
Accounts Payable
1.68
-58.76%
4.08
+12.03%
3.64
-79.12%
17.44
Current Accrued Expenses
7.25
-74.53%
28.47
+26.48%
22.51
-10.22%
25.07
Current Debt And Capital Lease Obligation
10.39
+19.78%
8.67
+55.25%
5.59
+37.71%
4.06
Current Debt
—
—
—
0.46
Other Current Borrowings
—
—
—
0.46
Current Capital Lease Obligation
10.39
+19.78%
8.67
+55.25%
5.59
+55.15%
3.60
Current Deferred Liabilities
—
—
7.73
+81.50%
4.26
Current Deferred Revenue
—
—
7.73
+81.50%
4.26
Other Current Liabilities
—
—
66.92
+92.47%
34.77
Total Non Current Liabilities Net Minority Interest
74.65
-11.97%
84.80
-72.18%
304.80
+20.76%
252.41
Liabilities Heldfor Sale Non Current
—
0.00
-100.00%
109.43
—
Long Term Debt And Capital Lease Obligation
72.58
-12.52%
82.97
-57.06%
193.20
+21.86%
158.53
Long Term Debt
—
—
101.54
+100.72%
50.59
Long Term Capital Lease Obligation
72.58
-12.52%
82.97
-9.48%
91.65
-15.09%
107.94
Non Current Deferred Liabilities
—
—
95.36
+3.17%
92.43
Non Current Deferred Revenue
—
—
95.36
+3.17%
92.43
Other Non Current Liabilities
2.08
+13.00%
1.84
+12.90%
1.63
+12.90%
1.44
Stockholders Equity
44.22
+220.79%
13.78
+130.73%
-44.86
-515.99%
10.78
Common Stock Equity
44.22
+220.79%
13.78
+130.73%
-44.86
-515.99%
10.78
Capital Stock
0.01
+11.11%
0.01
-93.33%
0.14
+8.00%
0.12
Common Stock
0.01
+11.11%
0.01
-93.33%
0.14
+8.00%
0.12
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
9.56
+10.47%
8.65
+28.11%
6.75
+7.84%
6.26
Ordinary Shares Number
9.56
+10.47%
8.65
+28.11%
6.75
+7.84%
6.26
Additional Paid In Capital
1,016.61
+2.49%
991.87
+6.28%
933.24
+6.63%
875.18
Retained Earnings
-972.40
+0.58%
-978.10
+0.01%
-978.24
-13.15%
-864.51
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-0.01
Other Equity Adjustments
—
—
—
-0.01
Total Equity Gross Minority Interest
44.22
+220.79%
13.78
+130.73%
-44.86
-515.99%
10.78
Total Capitalization
44.22
+220.79%
13.78
-75.68%
56.69
-7.64%
61.37
Working Capital
30.05
+1279.51%
-2.55
-103.32%
76.75
-29.69%
109.17
Invested Capital
44.22
+220.79%
13.78
-75.68%
56.69
-8.32%
61.83
Total Debt
82.97
-9.47%
91.64
-53.90%
198.78
+22.26%
162.59
Capital Lease Obligations
82.97
-9.47%
91.64
-5.76%
97.24
-12.82%
111.54
Net Tangible Assets
44.22
+220.79%
13.78
+130.73%
-44.86
-515.99%
10.78
Tangible Book Value
44.22
+220.79%
13.78
+130.73%
-44.86
-515.99%
10.78
Available For Sale Securities
—
—
—
—
Derivative Product Liabilities
—
0.00
-100.00%
0.55
0.00
Duefrom Related Parties Current
—
—
8.67
0.00
Dueto Related Parties Current
—
—
28.05
-19.32%
34.77
Investmentin Financial Assets
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1.12
+100.75%
-148.61
-26.63%
-117.35
+48.71%
-228.82
Cash Flow From Continuing Operating Activities
1.12
+100.75%
-148.61
-26.63%
-117.35
+48.71%
-228.82
Net Income From Continuing Operations
5.70
+4088.24%
0.14
+100.12%
-113.72
+54.54%
-250.16
Depreciation Amortization Depletion
4.13
-24.41%
5.47
-12.41%
6.24
-5.82%
6.63
Depreciation
4.13
-24.41%
5.47
-12.41%
6.24
-5.82%
6.63
Depreciation And Amortization
4.13
-24.41%
5.47
-12.41%
6.24
-5.82%
6.63
Other Non Cash Items
8.42
-20.89%
10.64
-29.83%
15.17
+118.78%
6.93
Stock Based Compensation
10.84
-48.31%
20.97
-38.50%
34.10
+33.82%
25.48
Asset Impairment Charge
0.00
-100.00%
3.27
0.00
0.00
Operating Gains Losses
-0.19
+99.84%
-123.58
-174163.38%
0.07
—
Gain Loss On Investment Securities
—
-0.55
+64.86%
-1.55
—
Gain Loss On Sale Of PPE
-0.19
-160.57%
0.32
0.00
0.00
Change In Working Capital
-27.78
+57.59%
-65.51
-11.08%
-58.98
-220.68%
-18.39
Change In Receivables
1.55
-76.52%
6.61
+176.16%
-8.67
0.00
Changes In Account Receivables
1.55
+175.00%
-2.07
0.00
0.00
Change In Inventory
0.00
+100.00%
-33.80
-13.99%
-29.65
0.00
Change In Prepaid Assets
2.72
+175.58%
0.99
+103.39%
-29.12
-131.16%
-12.60
Change In Payables And Accrued Expense
-23.38
+18.95%
-28.84
-777.09%
4.26
-23.09%
5.54
Change In Accrued Expense
-20.98
+19.01%
-25.90
-263.56%
15.84
+374.76%
3.34
Change In Payable
-2.40
+18.47%
-2.94
+74.61%
-11.58
-625.56%
2.20
Change In Account Payable
-2.40
+18.47%
-2.94
+74.61%
-11.58
-625.56%
2.20
Change In Other Working Capital
—
-4.12
-164.39%
6.41
+189.86%
-7.13
Change In Other Current Liabilities
-8.67
-36.84%
-6.34
-188.53%
-2.20
+47.73%
-4.20
Investing Cash Flow
-0.04
-100.03%
142.29
+1244.67%
10.58
-87.16%
82.43
Cash Flow From Continuing Investing Activities
-0.04
-100.03%
142.29
+1244.67%
10.58
-87.16%
82.43
Net PPE Purchase And Sale
-0.04
+88.95%
-0.38
+95.24%
-7.97
+18.80%
-9.82
Purchase Of PPE
-0.25
+33.68%
-0.38
+95.24%
-7.97
+18.80%
-9.82
Sale Of PPE
0.21
0.00
0.00
—
Capital Expenditure
-0.25
+33.68%
-0.38
+95.24%
-7.97
+18.80%
-9.82
Net Investment Purchase And Sale
0.00
0.00
-100.00%
18.56
-79.88%
92.25
Purchase Of Investment
0.00
0.00
+100.00%
-4.43
+90.82%
-48.22
Sale Of Investment
0.00
0.00
-100.00%
22.98
-83.64%
140.47
Net Business Purchase And Sale
0.00
-100.00%
141.27
0.00
0.00
Gain Loss On Sale Of Business
0.00
+100.00%
-146.71
0.00
0.00
Net Other Investing Changes
—
1.40
—
—
Financing Cash Flow
13.90
+115.38%
-90.37
-226.03%
71.70
-44.67%
129.60
Cash Flow From Continuing Financing Activities
13.90
+115.38%
-90.37
-226.03%
71.70
-44.67%
129.60
Net Issuance Payments Of Debt
0.00
+100.00%
-127.91
-353.19%
50.52
+96.58%
25.70
Issuance Of Debt
0.00
0.00
-100.00%
103.38
+274.48%
27.61
Repayment Of Debt
0.00
+100.00%
-127.91
-141.97%
-52.86
-2671.89%
-1.91
Long Term Debt Issuance
0.00
0.00
-100.00%
103.38
+274.48%
27.61
Long Term Debt Payments
0.00
+100.00%
-127.91
-141.97%
-52.86
-2671.89%
-1.91
Net Long Term Debt Issuance
0.00
+100.00%
-127.91
-353.19%
50.52
+96.58%
25.70
Net Common Stock Issuance
13.17
-44.04%
23.53
+29.58%
18.16
-82.05%
101.17
Proceeds From Stock Option Exercised
0.73
+50.10%
0.49
-83.92%
3.03
+10.71%
2.73
Net Other Financing Charges
—
13.52
—
—
Changes In Cash
14.97
+115.49%
-96.69
-175.72%
-35.07
-108.91%
-16.79
Effect Of Exchange Rate Changes
0.00
+100.00%
-0.00
-150.00%
0.00
+300.00%
-0.00
Beginning Cash Position
39.46
-71.02%
136.15
-20.48%
171.22
-8.93%
188.00
End Cash Position
54.43
+37.94%
39.46
-71.02%
136.15
-20.48%
171.22
Free Cash Flow
0.86
+100.58%
-148.99
-18.88%
-125.33
+47.48%
-238.64
Interest Paid Supplemental Data
0.00
-100.00%
10.86
-13.46%
12.55
+154.71%
4.93
Amortization Of Securities
0.00
0.00
+100.00%
-0.24
-134.30%
0.69
Common Stock Issuance
13.17
-44.04%
23.53
+29.58%
18.16
-82.05%
101.17
Issuance Of Capital Stock
13.17
-44.04%
23.53
+29.58%
18.16
-82.05%
101.17
Sale Of Business
0.00
-100.00%
141.27
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category